

YAKSU MEDICAL RESEARCHER — ENGLISH FACT SHEET

VOM / VOM Filler — crosslinked HA dermal filler family — CG Bio Co., Ltd. (CGBIO), Republic of Korea

Cut-off: 24 September 2026 (KST). Companion to vom-filler.md. Not an IFU. GLOBAL English only. Cosmetics / toxins / CaHA / PN boosters EXCLUDED.

1. Identity

Brand: VOM (official all-caps on manufacturer EN brochure and CGBIO aesthetics menu); also styled VOM Filler; Korean tradename bom (Hangul on KO packs).

Manufacturer: CG Bio Co., Ltd. (CGBIO), 211 Itaewon-ro, Yongsan-gu, Seoul, Republic of Korea — <https://www.cgbio.co.kr/> · brochure <https://cgbio.co.kr/VOM.pdf>

Not Across / Hugel: Across Co., Ltd. / Hugel Inc. make THE CHAEUM® / Revolax / Dermalax — they do not manufacture VOM.

Domestic marketer (Korea): DNC / DN Company / DNC Aesthetics (MOU 2020; 2023 renewal press).

Class: Medical-device BDDE-crosslinked hyaluronic acid gel for facial soft-tissue correction (not toxin, not CaHA, not PN).

2. Same-class SKUs (EN brochure core)

Grade	HA	Purpose (brochure)	Depth	Needles
VOM V	20 mg/mL	Fine wrinkle correction	Mid dermis	27G ½' / 30G ½'
VOM O	20 mg/mL	Deep wrinkle correction	Deep dermis	27G ½' × 2
VOM M	20 mg/mL	Volumizing & contouring	Sub-Q	25G ½' × 2

All three grades: Multi-Layered Phasic · R² Technology (Rotation & Revolution) — manufacturer EN brochure.

Alternate carton naming (DNC Dec 2023 KO press): Light / Intensive / Volume — same three-rung facial HA family; verify carton.

Lidocaine: present (CE press + brochure mixing claim) — % not independently verified on EN brochure.

Syringe fill / storage / shelf months: not independently verified on EN brochure — carton IFU prevails.

MoD (brochure DoF): V 2.14% · O 2.44% · M 2.45% — do not convert to residual BDDE ppm.

3. Technology (claims)

EN brochure: multi-layered phasic structure (crosslinked gel surrounds crosslinked particles); patented R² orbital mixing; BDDE crosslinker; lidocaine mixed by R²; ISO 13485 / MFDS-certified cGMP / WFI claims.

DNC 2023 renewal press (KO): biphasic→monophasic remake; process name PRISM (Pure and Real Injection for the Superior Moment — DocDocDoc 11 Dec 2023). Do not mix R² multiphasic and PRISM monophasic slogans without checking carton generation.

4. Regulatory

Korea MFDS: medical-device HA filler (brochure cites MFDS clinical report / facility certification) — licence number not independently verified.

CE: CGBIO announced CE markings for Gisellelign and VOM on 24 May 2021 (<https://www.cgbio.co.kr/en/13704>). Print “CE (manufacturer announcement, May 2021)”. Certificate serial / NB number: not independently verified.

US FDA PMA: NO / not independently verified as US-approved filler. CE press FDA language concerns Gisellelign plans, not VOM approval.

Secondary press also names product certifications in Indonesia, Philippines, Vietnam, Colombia — franchise-level; not SKU DoC.

5. Clinical evidence

VOM-specific PubMed RCT: none retrieved (24 Sep 2026 eSearch).

Manufacturer brochure VAS 2.3 vs comparator 4.5 — “MFDS clinical report” / “publication in progress”; n not stated.

Sister brand only: Yi et al., JPRAS 2023, PMID 37156109 — Gisellelign midface RCT — do not cite as VOM efficacy.

Independent peer-reviewed G' for VOM: not independently verified. Brochure DoF G' examples 239 / 416 / 572 Pa — manufacturer data on file only.

Labelled duration in months: not independently verified.

6. Safety (high level)

Local anaesthetic present → anaesthetic allergy is a class stop. Brochure MoD narrative is manufacturer framing, not a residual-ppm assay. Hyaluronidase reversibility graph is DoF (300 IU / 2 h claim) — not a clinic emergency algorithm.

Vascular-occlusion preparedness is standard HA clinic protocol; not a VOM-specific IFU quote retrieved here. English IFU contraindication list: not independently retrieved — carton prevails.

7. Do-not-print

FDA approved / PMA / 510(k) invention · invented CE serial or NB digits · grey-shop duration months · grey-shop lidocaine 0.3% or 1.0 mL×2 as manufacturer facts without carton · residual BDDE ppm invention · independent G' without PMID · Gisellelign trial n as VOM evidence · Across/Hugel attribution · merging FACETEM / Volassom / DClassy CaHA, CELLUNIT, toxins · grey-market leaflets · stamping “injectable” as a poster badge.

8. Class-split candidates (separate dossiers)

GISELLELIGN (sister HA brand) · AILEENE (separate HA brand if stocked) · FACETEM / FACETEM S (CaHA) · Volassom / DClassy CaHA · CELLUNIT (SVF) · any botulinum toxin.

9. Gaps / lock

Gaps: EN IFU; MFDS licence number; CE DoC/serial/NB; lidocaine %; syringe volume; storage/shelf; VOM RCT n; independent G'; residual BDDE ppm; current export generation (R² V/O/M vs PRISM Light/Intensive/Volume).
Conditional lock for GLOBAL English wholesale copy if poster text stays inside vom-filler.md §8 POSTER FACTS and carton IFU is checked. Not absolute lock until EN IFU + CE DoC + MFDS number + carton generation verified.

Primary PDF on file: yaksu-vom-filler-cgbio-brochure-2022.pdf (<https://cgbio.co.kr/VOM.pdf>). This fact sheet is research support for Yaksu Medi GLOBAL wholesale — not a regulatory submission and not an IFU.